HDAC6 inhibitors | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

13,833 results for “HDAC6 inhibitors”

Trials

View all 6406 →

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

1 participants · First posted Oct 18, 2016

Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours

20 participants · First posted Jan 2, 2017

A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer

First posted Dec 4, 2019

Drugs

View all 3228 →

HDAC6 inhibitors (neurological disorder)

HDAC6 inhibitors(Sungkyunkwan University)

HDAC6 inhibitors(Taipei Medical University)

Organizations

KalVista Pharmaceuticals

United States

Exelixis, Inc.

United States

Cytokinetics, Incorporated

United States

News

View all 4191 →

Augustine Therapeutics Raises €78 Million Series A to Advance Novel HDAC6 Inhibitor for Charcot-Marie-Tooth Disease

Augustine Therapeutics Appoints Rie Schultz Hansen as CSO, Establishes Copenhagen Subsidiary to Advance HDAC6 Inhibitor Pipeline

HDAC6 Identified as Biomarker for B-ALL Dissemination and Relapse Risk

Page 1 of 1384